|
|
|
| Effects of Olanzapine and Risperidone on Serum Levels of BDNF, NGF and IL-6 in Patients with Schizophrenia |
| ZHU Miao, YIN An-min, ZHANG Dong-liang |
| Department of Psychiatry,the Third People's Hospital of Huai'an City,Jiangsu Province, 223001 |
|
|
|
|
Abstract 【Objective】 To compare the effect of olanzapine and risperidone on serum brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), interleukin-6 (IL-6) levels and clinical application effect in patients with schizophrenia. 【Methods】 Seventy-two patients with schizophrenics admitted to our hospital from March 2016 to September 2018 were enrolled for the study and randomly divided into risperidone group (n=36) and olanzapine group (n=36), and they were treated with risperidone and olanzapine respectively for 6 months. The serum levels of BDNF, NGF, IL-6, the score of positive and negative symptom scale (PANSS) and the incidence of adverse reactions were compared before and after intervention between two groups. 【Results】 There were no significant differences in baseline data, total score of PANSS, serum levels of BDNF, NGF and IL-6 between two groups (P>0.05). For intra-comparison, the PANSS total score and serum level of IL-6 at 1, 3, 6 months after intervention in two groups were significantly lower than that before intervention, and serum levels of BDNF and NGF at 1, 3, 6 months after intervention were significantly higher than that before intervention (P<0.05). For inter-comparison, the PANSS total score and serum level of NGF at 6 months after intervention in olanzapine group were significantly higher than that in the risperidone group at the same time, the serum level of BDNF at 3 and 6 months after intervention in the olanzapine group was significantly higher than that of the risperidone group at the same time, and the serum level of IL-6 at 6 months after intervention in the olanzapine group was significantly lower than that in the risperidone group at the same time (P<0.05). The incidence of extrapyramidal system in the olanzapine group was significantly lower than that in the risperidone group (P<0.05), and there were no significant differences in other adverse reactions including headache, dizziness, abnormal sleep, increased body mass and dry mouth between two groups (P>0.05). 【Conclusion】 Olanzapine can significantly reduce the serum levels of BDNF, NGF and L-6 in schizophrenic patients. Olanzapine can better alleviate the symptoms of schizophrenia. The long-term effect of olanzapine is better than risperidone, and the safety is higher.
|
|
Received: 15 June 2020
|
|
|
|
|
|
[1] 张楠,向应强,马辛,等.精神分裂症社区康复技术对患者自知力和社会功能康复的作用[J].中国医学前沿杂志(电子版),2016,8(2):39-42.
[2] 沈君,廖东升,阿怀红.奥氮平治疗首发精神分裂症患者临床疗效观察[J].青海医药杂志,2013,43(4):32-33.
[3] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版:精神障碍分类[J].中华精神科杂志,2001,34(3):184-188.
[4] 付旭,秦晓霞.氯氮平与氯丙嗪对维持治疗期老年精神分裂症患者认知功能的影响分析[J].中国医学前沿杂志(电子版),2016,8(12):145-148.
[5] Kahn RS.The neurobiology and treatment of first-episode schizophrenia[J].Mol Psychiatry,2015, 20(1):84-97.
[6] 王莹,边艳辉,江芮.奥氮平与利培酮治疗精神分裂症患者认知功能的疗效比较[J].中国药房,2017,28(36):5083-5086.
[7] 唐自玲.奥氮平片治疗精神分裂症的效果观察[J].河南医学研究, 2018, 27(12): 2234-2235.
[8] 李涛,李界兴,尚同军,等.奥氮平片与利培酮片治疗男性精神分裂症疗效、安全性及对患者生活质量影响对比研究[J].陕西医学杂志,2019,48(5):657-660.
[9] 董辛.奥氮平与利培酮对分裂样精神障碍患者的疗效及安全性对比[J].航空航天医学杂志,2019,30(7):838-840.
[10] Ascoli BM. The role of macrophage polarization on bipolar disorder: Identifying new therapeutic targets[J].Aust N Z J Psychiatry,2016, 50(7): 618-630.
[11] Arisi, GM. Nervous and immune systems signals and connections: Cytokines in hippocampus physiology and pathology [J].Epilepsy Behav,2014, 38:43-47.
[12] Miller BJ.Meta-analysis of monocytes and lymphocytes in schizophrenia: clinical status and antipsychotic effects [J]. Biol Psychiatry,2011,70(7):663-671.
[13] 潘丽红,徐斐康,张毅,等.血清白细胞介素-6水平在急性期精神分裂症患者奥氮平治疗前后的变化[J].临床精神医学杂志,2018,28(6):374-377. |
|
|
|
2020, Vol. 37 
